Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin

Author(s): Agnieszka Korolczuk, Jaroslaw Dudka

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 4 , 2014

Become EABM
Become Reviewer


Leptin is a small peptide hormone (16 kDa), a product of the obesity gene (Ob), and is mainly synthesized and secreted by adipocytes. It is removed from the blood by the kidneys. The kidney is not only a site of leptin clearance, but also a target organ for its action in different pathophysiological states. Several studies have documented a strong relationship between chronic kidney disease (CKD) and accelerated cardiovascular disease (CVD) defined as a cardiorenal syndrome. Patients with stage 3 and 4 CKD develop cardiovascular complications and are at increased risk of death from CVD. Renal dysfunction promotes several mechanisms responsible for exacerbation of cardiovascular disease. These include activation of the renin-angiotensin system, oxidative stress, elevated asymmetric dimethylarginine (ADMA), low-grade inflammation with increased circulating cytokines, and dyslipidemia. Recently, it has been observed that plasma leptin level is elevated in patients with cardiorenal syndrome. In obesity, hyperleptinemia combined with selective leptin resistance appear to have a critical role in the development and progression of kidney disease, CVD and metabolic syndrome. This has clinical implications for the treatment of obesity–related hypertension and kidney disease. In this paper the role of leptin in chronic kidney disease and accelerated cardiovascular disease is out lined. The link between hyperleptinemia and development and progression of morphologic changes that effect kidney in obese patients is also discussed.

Keywords: Leptin, cardiovascular disease, chronic kidney disease, obesity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [666 - 674]
Pages: 9
DOI: 10.2174/13816128113199990013
Price: $65

Article Metrics

PDF: 27